Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase 1 2

Status

Completed 5Terminated 1

Sponsor Class

INDUSTRY 5OTHER 1

Study Type

Interventional 6

Sponsor

Cancer Type

Gastrointestinal 4Tumor-Agnostic 2

Conditions

Stomach Neoplasms 13Carcinoma, Non-Small-Cell Lung 13Carcinoma, Hepatocellular 6Adenocarcinoma 6Neoplasms 5Lung Neoplasms 4Colorectal Neoplasms 4Colonic Neoplasms 4Breast Neoplasms 4Urethral Neoplasms 3Rectal Neoplasms 3Neoplasm Metastasis 3Liver Neoplasms 3Carcinoma, Renal Cell 3Urinary Bladder Neoplasms 2Ureteral Neoplasms 2Solid Tumors 2Sarcoma 2Non-small Cell Lung Cancer Metastatic 2Malignant Solid Tumor 2Esophageal Neoplasms 2Carcinoma, Transitional Cell 2Biliary Tract Neoplasms 2Thymoma 1Solid Tumor 1Sarcoma, Synovial 1Recurrence 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1

Interventions

Gemcitabine 14Cisplatin 13Capecitabine 11Oxaliplatin 9Fluorouracil 9130-nm albumin-bound paclitaxel 9Paclitaxel 8pembrolizumab 7Ramucirumab 6Leucovorin 6Carboplatin 6Bevacizumab 6Albumin-Bound Paclitaxel 6Pemetrexed 4Nivolumab 4Irinotecan 4Everolimus 4Erlotinib Hydrochloride 4Docetaxel 4Cyclophosphamide 4trastuzumab deruxtecan 3Radiotherapy 3Afatinib 3zolbetuximab 2pralsetinib 2cabozantinib 2Trastuzumab 2Ipilimumab 2vosaroxin 1vandetanib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Has results × Adenocarcinoma × Ramucirumab × Clear all
NCT05980416 2025-11-14

Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2

Elevation Oncology

Phase 1 Terminated
88 enrolled 18 charts
Gastrointestinal

Adenocarcinoma, Digestive System Neoplasms, Gastrointestinal Neoplasms, Neoplasms, Neoplasms by Site, Stomach Neoplasms

NCT02213289 2021-04-08

PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression

University of Chicago

Phase 2 Completed
80 enrolled 14 charts
Tumor-Agnostic

Adenocarcinoma

NCT00917384 2019-09-25

Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma

Eli Lilly and Company

Phase 3 Completed
355 enrolled 16 charts
Gastrointestinal

Adenocarcinoma, Neoplasm Metastasis, Stomach Neoplasms

NCT01170663 2019-09-18

RAINBOW

Eli Lilly and Company

Phase 3 Completed
665 enrolled 24 charts
Gastrointestinal

Adenocarcinoma, Stomach Neoplasms

NCT01111604 2019-08-06

A Study of Ramucirumab or Icrucumab in Colorectal Cancer

Eli Lilly and Company

Phase 2 Completed
158 enrolled 17 charts
Gastrointestinal

Adenocarcinoma, Colonic Neoplasms, Rectal Neoplasms

NCT01253525 2014-06-18

Study of Weekly Paclitaxel With Ramucirumab in Participants With Advanced Gastric Adenocarcinomas

Eli Lilly and Company

Phase 1 Completed
6 enrolled 18 charts
Tumor-Agnostic

Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡